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ABSTRACT 
Lafora disease (LD, OMIM254780, ORPHA501) is a rare neurodegenerative form of epilepsy 
related to mutations in two proteins: laforin, a dual specificity phosphatase, and malin, an E3-
ubiquitin ligase. Both proteins form a functional complex, where laforin recruits specific 
substrates to be ubiquitinated by malin. However, little is known about the mechanism driving 
malin-laforin mediated ubiquitination of its substrates. In this work we present evidence 
indicating that the malin-laforin complex interacts physically and functionally with the ubiquitin 
conjugating enzyme E2-N (UBE2N). This binding determines the topology of the chains that 
the complex is able to promote in the corresponding substrates (mainly K63-linked 
polyubiquitin chains). In addition, we demonstrate that the malin-laforin complex interacts 
with the selective autophagy adaptor sequestosome-1 (p62). Binding of p62 to the malin-
laforin complex allows its recognition by LC3, a component of the autophagosomal 
membrane. In addition, p62 enhances the ubiquitinating activity of the malin-laforin E3-
ubiquitin ligase complex. These data enrich our knowledge on the mechanism of action of 
the malin-laforin complex as an E3-ubiquitin ligase and reinforces the role of this complex in 
targeting substrates towards the autophagy pathway. 
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1.- INTRODUCTION 
Lafora disease (LD; OMIM 254780, ORPHA501) is a rare form of progressive 
myoclonus epilepsy, first described in 1911 by the Spanish neurologist Gonzalo R. Lafora 
(Lafora and Glueck, 1911). The first symptoms of the disease appear at early adolescence, 
producing myoclonus, tonic-clonic seizures and epileptic crises, and a progressive dementia, 
apraxia, aphasia and visual loss (Monaghan and Delanty, 2010). Histologically, the most 
characteristic hallmark of LD is the accumulation of aberrant glycogen forms named Lafora 
bodies (LBs) (Minassian, 2001). However, at present, it is still not clear whether the 
accumulation of LBs is the cause of the disease or a consequence of previous alterations. In 
the vast majority of cases, the disease is produced by mutations either in the EPM2A gene, 
which encodes the dual specificity phosphatase laforin (Minassian et al., 1998, Serratosa et 
al., 1999), or in the EPM2B gene, encoding the E3 ubiquitin ligase malin (Chan et al., 2003). 
Patients with mutations in either EPM2A or EPM2B genes are histologically and 
neurologically indistinguishable, suggesting that both proteins are involved in the same 
physiological pathways  (Gómez-Abad et al., 2005). It has been described that laforin and 
malin form a functional complex in which laforin targets malin to the appropriate substrates 
for their ubiquitination. Several substrates of the malin-laforin complex have been described 
(Romá-Mateo et al., 2012), including proteins involved in glycogen synthesis. Thereby, the 
loss of either laforin or malin results in a dysregulation of glycogen metabolism, leading to the 
formation of LBs (Lohi et al., 2005, Rubio-Villena et al., 2013, Solaz-Fuster et al., 2008, 
Worby et al., 2008). Other processes have been shown to be affected by mutations in laforin 
and malin. For instance, the malin-laforin complex participates in the clearance of misfolded 
proteins through the ubiquitin-proteasome pathway: dysfunction of the malin-laforin complex 
results in a reduction of proteasomal activity leading to increased sensitivity to endoplasmic 
reticulum stress (Garyali et al., 2009, Vernia et al., 2009). In addition, a clear impairment in 
autophagy has also been described both in malin and laforin knock-out mice (Aguado et al., 
2010, Criado et al., 2012), as well as the appearance of oxidative stress (Romá-Mateo et al., 
2015a). Taken together, these evidences suggest a broad impairment of the protein 
clearance systems when the malin-laforin complex is not functional, indicating that there are 
more processes implicated in the disease other than glycogen synthesis and accumulation 
(Romá-Mateo et al., 2015b). 
Ubiquitination is a highly conserved process in eukaryotic organisms, which depends 
on the sequential activity of three different enzymes: an ubiquitin-activating enzyme (E1), an 
ubiquitin-conjugating enzyme (E2) and an ubiquitin ligase (E3). E1s use ATP to bind a 
molecule of ubiquitin to the Cys residue in their active site. Then, this ubiquitin is transferred 
to the Cys residue of an E2. The third step depends on the type of E3 involved: E3s with a 
HECT domain incorporate themselves the ubiquitin from the E2, before transferring it to the 
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substrate. However, E3s with a RING domain, like malin, act as scaffolds bringing together 
the substrate and an activated E2, so the ubiquitin can be transferred directly from the E2 to 
a Lys residue of the substrate (Ye and Rape, 2009). In this type of E3 ubiquitin ligases, the 
specific combination of the E2 and the E3 determines the topology and length of the ubiquitin 
chains conjugated to the substrate [see (Deshaies and Joazeiro, 2009, Metzger et al., 2014, 
Ye and Rape, 2009) for review]. The function of the ubiquitin chains depends on their 
topology, which might either label proteins for proteasomal degradation or target them to 
participate in alternative cellular functions (DNA repair, cell signaling, etc.) (Deshaies and 
Joazeiro, 2009, Ye and Rape, 2009). For instance, poly-ubiquitin chains linked through 
Lys63 direct the substrate to autophagy (Pickart and Fushman, 2004). 
Autophagy is a degradation pathway existing in all eukaryotic organisms. It is the 
main system for the degradation of bulk cytoplasmic components in cells (Feng et al., 2014), 
but it also plays a crucial role in other processes, as immunity (Wileman, 2013), 
mitochondrial (Dengjel and Abeliovich, 2014) and peroxisomal (Till et al., 2012) degradation 
and clearance of misfolded protein aggregates (Lamark and Johansen, 2012). These 
pathways of selective autophagy, in contrast to the more or less random sequestration of 
cytosol components produced by the bulk autophagy, are regulated by the participation of 
specific adaptors. The first protein reported to have this adaptor function was p62 (also 
named sequestosome-1, SQSTM1) (Pankiv et al., 2007), which, in addition to its implication 
in cell growth and proliferation, was detected in ubiquitinated protein aggregates (Moscat and 
Diaz-Meco, 2009). p62 possesses, among other interacting motifs, a C-terminal ubiquitin-
binding domain (UBA) which allows its interaction with ubiquitinated substrates [containing 
mainly K63-linked polyubiquitin chains (Seibenhener et al., 2004)] and a short LIR (LC3-
interacting region) sequence (Ciani et al., 2003) which allows its interaction with LC3 (Pankiv 
et al., 2007), a protein anchored in the autophagosomal membrane (Kirisako et al., 1999). In 
addition, p62 contains an N-terminal PB1 domain that allows homopolymerization of the 
protein (Johansen and Lamark, 2011). It has been reported that once p62 binds to 
ubiquitinated proteins, it oligomerizes serving these oligomers as a nucleating factor for 
autophagosome formation (Lippai and Low, 2014). 
In this work, we aimed to deepen our knowledge on the functional regulation of the 
malin-laforin complex. First, we focused our attention on the E2-conjugase that participates 
in the ubiquitination reaction. We found that the ubiquitin conjugating enzyme E2-N (UBE2N; 
Ubc13), one of the more than 38 different E2 conjugating enzymes which are encoded in the 
human genome (Ye and Rape, 2009), interacts with the malin-laforin complex and modulates 
its function. Second, we have also found a physical and functional interaction between p62 
and the malin-laforin complex, highlighting the relationship between this complex and 
autophagy. 
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2.- MATERIALS AND METHODS 
2.1.- Plasmids 
Plasmids pCMV-myc-laforin, pCMV-HA-laforin, pFLAG-laforin, pcDNA3-HA-malin, pFLAG-
malin and pCMV-myc-R5/PTG are described in (Solaz-Fuster et al., 2008). Plasmid pCMV-
6xHisUbiq was kindly provided by Dr. Manuel Rodriguez (Proteomics Unit, CIC-BioGUNE, 
Vizcaya, Spain), plasmids pCMV-6xHis-Ubiq-K48R and pCMV-6xHis-Ubiq-K63R were a 
generous gift of Dr. Ch. Blattner (Institute of Toxicology and Genetics, Karlsruhe Institute of 
Technology, Karlsruhe, Germany), plasmid pcDNA3-myc-p62 was kindly provided by Dr. 
Jorge Moscat (Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA), 
plasmid pEGFP-LC3 was donated by Dr. Erwin Knecht (Centro de Investigación Principe 
Felipe, Valencia, Spain) and plasmids pV5-DEST-UBE2D2 and pV5-DEST-UBE2D2-C85A 
were a generous gift from Dr. Peter Tontonoz (Howard Hughes Medical Institute, UCLA, Los 
Angeles, CA 90095, USA). Plasmid pECFP-laforin was obtained by digesting plasmid 
pEG202-laforin [described in (Solaz-Fuster et al., 2008)] with BglII/BamHI and subcloning 
into plasmid pECFP-N1 (BD Biosciences, Madrid, Spain). 
UBE2N cDNA was acquired from the Mammalian Gene Collection (cDNA clone 
MGC:8489; IMAGE:2822013) and amplified by PCR using the following oligonucleotides: 
forward 5’-GGCGAATTCATGGCCGGGCTGCCCCGC-3’ and reverse 5’- 
CCGCTCGAGTTAAATATTATTCATGGCATATAGCCT-3’. The amplified fragment was 
digested with EcoRI/XhoI and subcloned into pGEM-T-Easy vector, digested with the same 
set of enzymes. The construct was sequenced to ensure that no mutations were introduced 
during amplification. An EcoRI/XhoI fragment containing UBE2N ORF was then subcloned 
into vector pGADT7 (Clontech, Madrid, Spain) to obtain plasmid pGADT7-UBE2N. An 
SfiI/XhoI fragment from the latter was subcloned into pCMV-myc and pCMV-HA vectors (BD 
Biosciences, Madrid, Spain), obtaining plasmids pCMV-myc-UBE2N and pCMV-HA-UBE2N, 
respectively. An EcoRI/BamHI fragment from pGADT7-UBE2N was subcloned into vector 
pECFP-N1 to obtain plasmid pECFP-N1-UBE2N. UBE2N-C87A was obtained by site 
directed mutagenesis using pCMV-myc-UBE2N as template, the Quick Change kit 
(Stratagene) and the following mutagenic oligonucleotides: forward 5’-
GTAGACAAGTTGGGAAGAATAGCTTTAGATATTTTGAAAGATAAG-3’ and reverse 5’-
CTTATCTTTCAAAATATCTAAAGCTATTCTTCCCAACTTGTCTAC-3’. The amplified 
fragment was digested with EcoRI/XhoI and subcloned into pGEM-T-Easy vector, digested 
with the same set of enzymes. The construct was sequenced to ensure that no other 
mutations were introduced during amplification. The pGEM-T-easy-UBE2N C87A plasmid 
was digested as described above for wild type UBE2N to obtain the corresponding plasmids 
based on the following vectors: pGADT7, pCMV-myc, pCMV-HA and pECFP-N1. 
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2.2.- Cell culture and immunodetection 
Human embryonic kidney (HEK293) cells were grown in DMEM (Lonza, Barcelona, 
Spain) supplemented with 100 units/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine, 
10% inactivated fetal bovine serum (GIBCO, Madrid, Spain) in a humidified atmosphere at 
37ºC with 5% CO2. Cells were transfected with 3 μg of each plasmid using X-treme GENE 
HP transfection reagent (Roche Diagnostics, Barcelona, Spain), according to the 
manufacturer’s instructions. Twenty-four hours after transfection, cells were scraped on ice in 
lysis buffer 1 [25 mM Tris-HCl pH 8, 5 mM NaF, 5 mM Na4P2O7, 0.5% Triton X100, 100 mM 
KCl, protease inhibitor cocktail (Roche Diagnostics, Barcelona, Spain) and 1 mM PMSF]. 
Cells were lysed by repeated passage through a 25-gauge needle and clarified by 
centrifugation at 13,000xg for 10 min at 4ºC. 50 µg of total protein from the soluble fraction of 
cell lysates were analyzed by SDS-PAGE and Western blotting using appropriated 
antibodies: anti-actin, anti-myc, anti-Flag, anti-HA (all from Sigma-Aldrich, Madrid, Spain), 
anti-laforin (Solaz-Fuster et al., 2008), anti-malin (NeuroMab, California, USA), anti-GFP 
(ImmunoKontact, Oxon, UK), anti-V5 (Invitrogen, Madrid, Spain) and anti-p62 (Abcam, 
Cambridge, UK) antibodies.  
 
2.3.- GFP-trap analysis 
HEK293 cells were transfected with specific constructs of laforin, malin, and the 
protein of interest (UBE2N, UBE2N-C87A or p62). Cells were scraped on ice in phosphate-
buffered saline (PBS), washed twice in PBS and then lysed using a 25-gauge needle in lysis 
buffer 2 [10 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 2.5% glycerol, 0.5% nonidet 
P-40 (NP-40), complete protease inhibitor cocktail (Roche Diagnostics, Barcelona, Spain), 1 
mM PMSF, 2.5 mM NaF, 0.5 mM NaVO4 and 2.5 mM Na4P2O7]. Cell lysates were then 
centrifuged at 13,000×g for 10 min at 4ºC. CFP-fused proteins were immunoprecipitated from 
supernatants (1.5 mg of total protein) by incubating with Chromotek GFP-trap beads 
(Chromotek, Planegg-Martinsried, Germany) for ten minutes in a rocking platform at 4ºC and 
visualized by immunoblotting using specific antibodies. As a negative control, a construct 
expressing CFP alone (plasmid pECFP-N1) was used to confirm the specificity of the 
interaction. 
 
2.4.- Analysis of ubiquitination 
To study ubiquitination, we followed the method described in (Kaiser and Tagwerker, 
2005). Briefly, HEK293 cells were transfected with plasmid pCMV-6xHis-Ubiq (encoding a 
modified ubiquitin tagged with 6xHis residues), and plasmids encoding laforin, malin and the 
protein of interest (R5/PTG, UBE2N, UBE2N-C87A, UBE2D2, UBE2D2-C85A or p62). After 
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24 hours of transfection, cells were lysed in buffer A (6 M guanidinium-HCl, 0.1 M sodium 
phosphate, 0.1 M Tris-HCl, pH 8.0) to inhibit the action of deubiquitinases. 1.5 mg of protein 
of a clarified extract (12,000xg, 15 min) were incubated with 150 μl of a TALON cobalt resin 
(Clontech, Barcelona, Spain) in buffer A in the presence of 10 mM imidazole (buffer B), for 3 
hours at room temperature on a rocking platform, to purify His-tagged proteins. The resin 
was then successively washed with 1 mL of buffer B and four times with buffer C (buffer B, 
but with 8 M urea instead of 6 M guanidinium-HCl). Bound proteins were boiled in 40 μl of 
2xLaemmli’s sample buffer and analyzed by Western blotting using appropriate antibodies. 
When indicated, plasmids pCMV-6xHis-Ubiq-K48R and pCMV-6xHis-Ubiq-K63R were used 
in the assay instead of pCMV-6xHis-Ubiq wild type, to determine the topology of the ubiquitin 
chains. 
 
2.5.- siRNA UBE2N silencing 
HEK293 cells were treated, in parallel, with a control siRNA (Ambion. Austin, TX, 
USA) or a specific siRNA against UBE2N (sense, 5’- CCUCUUUGUUUGCAUUUAA[dT][dT]-
3’; antisense, 5’- UUAAAUGCAAACAAAGAGG[dT][dT]-3’) (Sigma-Aldrich, Madrid, Spain). 
Cells were transfected at a confluence of 70% using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA. USA) according to manufacturer’s instructions. Twenty-four hours after 
transfection, cells were transfected with the indicated plasmids and the analysis of 
ubiquitination was performed as described above. 
 
2.6.- Immunofluorescence and confocal microscopy 
Human osteosarcoma U2OS cells were grown as indicated in the case of HEK293 
cells. They were transfected with the indicated plasmids and grown on 12-well plates 
containing coverslips. Cells were fixed with 4% paraformaldehyde in phosphate-buffered 
saline (PBS) for 10 min. Then cells were permeabilized with 0.2% Triton X-100 in PBS for 30 
min. Cells were washed three times with PBS and blocked one hour with 10% fetal bovine 
serum, 5% nonfat dried milk, 0.5% BSA and 0.1% Triton X-100 in PBS. Cells were then 
incubated overnight at 4 ºC with 1/500 dilution of anti-HA or anti-myc (Sigma–Aldrich, Madrid, 
Spain) in blocking solution. Samples were washed three times with PBS and incubated with 
a 1/1000 dilution of anti-mouse Texas Red or anti-rabbit Alexa-Fluor 633 (Invitrogen, Madrid, 
Spain), respectively. Finally, samples were washed three times with PBS and mounted on 
slices using Aqua-Poly/Mount coverslipping medium (Polysciences, Inc. Eppelheim, 
Germany). The co-localization assays were performed with a Leica TCS SP8 confocal 
microscope (Leica,Wetzlar, Germany) using a HCX PL APO 63x 1.4 NA oil objective. Images 
were treated with the ImageJ 1.49 software (Wayne Rasband, National Institutes of Health, 
USA). 
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3.- RESULTS 
3.1.- The E2-conjugase UBE2N modulates the E3-ubiquitin ligase activity of malin in 
human HEK293 cells. 
Malin is an E3-ubiquitin ligase of the RING type (Gentry et al., 2005, Solaz-Fuster et 
al., 2008). It is assumed that in RING-type ubiquitin ligases, the topology of the polyubiquitin 
chains they are able to promote depends on the specific interaction between the E3 and the 
corresponding E2-conjugases [see (Deshaies and Joazeiro, 2009, Metzger et al., 2014, Ye 
and Rape, 2009) for review]. Although it is known that malin forms a functional complex with 
laforin (a dual specificity phosphatase) and mediates the formation of K63-linked 
polyubiquitin chains into their corresponding substrates (Moreno et al., 2010, Romá-Mateo et 
al., 2011, Rubio-Villena et al., 2013), little is known about the E2-conjugases that participate 
in this reaction. So far, it is only known that malin may use the E2-conjugases UBE2H 
(UbcH2), UBE2D (UbcH5) and UBE2E1 (UbcH6) (in brackets the second name of the same 
enzyme), in in vitro polyubiquitination assays (Gentry et al., 2005, Solaz-Fuster et al., 2008). 
However, there are no reports on the specific E2-conjugase that associates with malin in 
vivo. As indicated above, malin promotes the formation of K63-linked polyubiquitin chains; 
thus, we wondered whether UBE2N (Ubc13), an E2 that specifically promotes the formation 
of this type of polyubiquitin linkages (Eddins et al., 2006, Petroski et al., 2007), associated 
with malin in vivo. To test this possibility we followed an approach based on the fact that 
when the active cysteine residue of a particular E2 is mutated to alanine, the conjugation 
activity is no longer functional and the overexpression of such a mutant acts as dominant 
negative for the particular E2-dependent ubiquitination (Slotman et al., 2012, Zhang et al., 
2013). Thus, we decided to overexpress UBE2N-C87A inactive mutant and check the 
efficiency of the malin-laforin dependent polyubiquitination of laforin. As shown in Fig. 1A and 
in agreement with previous reports, malin promoted the ubiquitination of laforin (compare 
lanes 1 and 2). Overexpression of UBE2N did not increase significantly the efficiency of the 
ubiquitination reaction (Fig. 1A, lane 3), probably because HEK293 cells may have enough 
endogenous UBE2N to assist the malin-laforin dependent ubiquitination. However, 
overexpression of the inactive UBE2N-C87A clearly reduced the ubiquitination of laforin 
(compare lanes 3 and 4). These data indicated that malin required a functional UBE2N to 
promote the incorporation of ubiquitin chains into laforin. 
We extended our analysis to another substrate of the malin-laforin complex such as 
R5/PTG, a regulatory subunit of type 1 protein phosphatase (Solaz-Fuster et al., 2008), 
observing again a dramatic reduction in the ubiquitination of this protein when the inactive 
UBE2N-C87A form was present (Fig. 1B, compare lanes 3 and 4). Interestingly, the 
overexpression of UBE2D2-C85A (an inactive form of UBE2D2 enzyme, another type of E2 
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conjugase) had no effect on the rate of ubiquitination of the malin-laforin substrates (see Fig. 
1B, lanes 5 and 6), highlighting the specificity of the effect observed with the UBE2N-C87A 
mutant form. These results collectively suggested the participation of UBE2N in the in vivo 
malin-dependent ubiquitination of substrates. 
To confirm the role of UBE2N in the malin-dependent polyubiquitination reaction, we 
silenced the expression of UBE2N by siRNA. Silencing efficiency was estimated around 73% 
as demonstrated by qRT-PCR analysis under the assayed conditions (not shown). We then 
overexpressed the malin-laforin complex in the silenced cells. As shown in Fig. 2A, specific 
downregulation of UBE2N expression diminished the efficiency of the malin-dependent 
ubiquitination of laforin (compare lanes 2 and 4). We repeated the same analysis for the 
modification of R5/PTG (Fig. 2B; compare lanes 2 and 4) with similar results. Therefore, a 
decrease in the expression of UBE2N impairs the malin-dependent ubiquitination of its 
substrates. 
 Finally we decided to check if there was any physical interaction between UBE2N and 
the malin-laforin complex. We performed yeast two-hybrid analysis between UBE2N, malin 
and laforin but we did not observe any positive reaction. As the putative interaction could be 
too transient to be recorded by the two-hybrid analysis, we decided then to make a protein 
fusion of UBE2N to CFP and use the GFP-trap assay (a particular kind of pull-down assay) 
to check the putative physical interaction. HEK293 cells were transfected with plasmids 
expressing malin and laforin and with plasmids expressing CFP-UBE2N-WT, CFP-UBE2N-
C87A or CFP alone. Crude extracts were obtained, pulled down with anti-GFP-beads (GFP-
trap) and proteins in the pellet were analyzed by immunoblotting using specific antibodies. As 
observed in Fig. 3, CFP-UBE2N was able to specifically pull down both malin and laforin, as 
these proteins were absent in the samples that expressed CFP alone (compare lanes 1 and 
2). Since the yield of the purification was higher for malin than for laforin, we suggest that 
UBE2N interacts better with malin, and probably the laforin species that are detected come 
down because of the interaction between malin and laforin (Fig. 3, lane 2). Surprisingly, the 
efficiency of the interaction with malin decreased dramatically when the UBE2N-C87A 
mutant was expressed (Fig. 3, compare lanes 2 and 3). As this mutant is unable to bind 
ubiquitin, this might reflect that the binding of malin to UBE2N is higher if this E2 is loaded 
with ubiquitin, as reported previously in the binding of other E2-E3 complexes (Eddins et al., 
2006).  
Taking all these results together, we suggest that UBE2N participates in the in vivo 
ubiquitination of malin-dependent substrates. 
 
3.2.- The selective autophagy modulator p62 (SQSTM1) enhances the malin-dependent 
ubiquitination reaction. 
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 It has been described that p62 (SQSTM1), a scaffolding protein involved in selective 
autophagy (Johansen and Lamark, 2011, Shaid et al., 2013, Stolz et al., 2014), interacts with 
the E3-ubiquitin ligase TRAF6 (which directs the synthesis of K63-linked polyubiquitin chains 
on specific substrates) and regulates its K63-polyubiquitination and oligomerization (Wooten 
et al., 2005). TRAF6 also associates with the E2 UBE2N in the polyubiquitination reaction 
(Deng et al., 2000). Due to the similarities in the mechanisms of action of TRAF6 and malin, 
we decided to check whether p62 could affect the efficiency of the polyubiquitination reaction 
mediated by malin. With this aim, we overexpressed p62 in HEK293 cells and compared the 
efficiency of the malin-laforin dependent ubiquitination of substrates in the presence or 
absence of this protein. As observed in Fig. 4, the expression of p62 enhanced both the 
malin-dependent ubiquitination of laforin (compare lanes 3-4 in first panel) and malin itself 
(compare lanes 1-2, and 3-4, in second panel). p62 was also ubiquitinated when 
overexpressed, but this reaction was strongly increased when both malin and laforin were 
present (compare lane 2 and lane 4 in third panel).  
We next determined whether the malin-laforin dependent ubiquitination of p62 was 
dependent on UBE2N. As shown in Fig. 5A, we observed a drastic reduction in the 
ubiquitination of p62 when the catalytically inactive UBE2N C87A was present in the assay 
(compare lanes 3 and 4), indicating a role of UBE2N in this modification. In addition we 
analyzed the topology of the ubiquitin chains that the malin-laforin complex was able to 
promote on p62. As shown in Fig. 5B, p62 was still fully polyubiquitinated when a modified 
K48R form of ubiquitin (which prevented the formation of K48-linked ubiquitin chains) was 
present in the assay (compare lanes 1 and 2), whereas p62 ubiquitination was drastically 
reduced when a modified K63R form of ubiquitin (which prevented the formation of K63-
linked ubiquitin chains) was present (compare lane 1 and 3). These results clearly indicate 
that the malin-laforin complex promotes the formation of K63-linked ubiquitin chains into p62. 
To understand the enhancer property of p62 on malin-dependent ubiquitination, we 
checked whether there was a physical interaction between p62 and the malin-laforin 
complex. As observed in Fig. 6, when crude extracts from HEK293 cells expressing CFP-
laforin, HA-malin and myc-p62 were pulled down with anti-GFP-beads (GFP-trap), both malin 
and p62 were recovered in the pellet (compare lanes 2 and 4). However, if malin was not 
overexpressed (lane 3), CFP-laforin was not able to pull down p62. These data suggested 
that malin was required to allow the interaction of p62 with laforin. We also observed that this 
tertiary complex (laforin-malin-p62) was still able to maintain a physical interaction with 
UBE2N (Fig. 6, lane 5), as this E2 was recovered in the pulldown pellet. Next, we wanted to 
assess if the interaction between p62 and the malin-laforin complex was dependent on the 
ubiquitination of these proteins, since as p62 possesses an ubiquitin-binding domain (UBA), 
the reported interaction could be mediated by the ubiquitin moieties. However, the 
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overexpression of UBE2N-C87A, which, as demonstrated above greatly diminished the 
malin-laforin complex ubiquitination activity, did not affect the interaction between p62 and 
the malin-laforin complex (Fig. 6 lane 6).  
 The interaction between the malin-laforin complex and p62 was confirmed by 
immunofluorescence. These experiments were performed with human osteosarcoma U2OS 
cells since they are larger and allow a better observation of the subcellular compartments 
[similar malin-laforin dependent ubiquitination of p62 was observed in these cells (not 
shown)]. U2OS cells were transfected with the corresponding plasmids and the associated 
fluorescence to each protein visualized by confocal microscopy. As shown in Fig. 7 (panel 1), 
in cells expressing HA-malin and myc-p62 alone, malin showed a mainly nuclear localization 
of the protein, as previously described (Sengupta et al., 2011) and p62 showed a punctuated 
distribution; however no major co-localization of both proteins was observed. Interestingly, 
when U2OS cells co-expressed CFP-laforin at the same time, all the proteins (laforin, malin 
and p62) localized in similar punctuated structures and malin was not longer localized inside 
the nucleus (Fig. 7, panel 2). When CFP-laforin was co-expressed only with HA-malin (Fig. 7, 
panel 3) or only with myc-p62 (Fig. 7, panel 4) similar punctuated structures were observed 
that contained the two proteins under study. However, the expression of CFP-laforin alone 
did not produce these structures (Fig. 7, panel 5). These results indicate that the combined 
expression of CFP-laforin with any of the other proteins results in punctuated structures 
which recruit malin and p62. 
 Since p62 is a selective adaptor of autophagy that interacts with LC3 (Pankiv et al., 
2007), a protein anchored in the autophagosomal membrane (Kirisako et al., 1999), we 
decided to check whether the punctuated structures that contained laforin, malin and p62 
were related to autophagy. With this aim we transfected U2OS cells with a plasmid 
expressing GFP-LC3 and checked whether the expression of laforin, malin and p62 co-
localized with this autophagy marker. As shown in Fig. 8 (panel 1), GFP-LC3 clearly co-
localized with p62 as already known. However, cells expressing laforin and malin did not 
show any co-localization with GFP-LC3 (Fig. 8, panel 2). The co-expression of p62 in these 
cells resulted in a co-localization of LC3, p62, malin and laforin in punctuated structures (Fig. 
8, panel 3). If cells expressed GFP alone instead of GFP-LC3, the punctuated structures 
containing p62, malin and laforin were still visible, although they did not co-localize with GFP 
fluorescence, confirming the results presented in Fig. 7 panel 2. These results indicate that 
the expression of laforin, malin and p62 produces punctuated structures that are recognized 
by the autophagy machinery (LC3).  
Taking together, these results suggest that there is a physical and functional 
interaction between the malin-laforin complex, p62 and the autophagosome. 
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4.- DISCUSSION 
Pathophysiology of LD involves alterations in many cellular processes, among which 
glycogen metabolism and protein homeostasis (proteostasis) mechanisms seem to play a 
central role. In the last years, growing evidence of numerous and particularly diverse 
molecular pathways such as the unfolded protein and heat-shock responses (Sengupta et 
al., 2011), antioxidant defense systems (Romá-Mateo et al., 2015a) and autophagy (Aguado 
et al., 2010, Criado et al., 2012) have been reported to be altered as a consequence of 
mutations in either malin and laforin, the two proteins related to the disease. Most of these 
alterations correlate with a dysfunction of the E3-ubiquitin ligase complex formed by malin 
and laforin; however, there is scarce evidence reporting the specific molecular determinants 
that participate in the ubiquitination reaction mediated by the complex and how it takes place. 
Ubiquitination is a versatile modification that can lead substrates to a wide variety of 
destinations. Knowing the modulators that participate in the malin-laforin mediated 
ubiquitination will allow us to better understand the multiple physiological roles of these 
proteins, providing novel insights and deeper knowledge of the pathophysiology of LD as well 
as widening our understanding of the complex interactions that drive specific intracellular 
signaling pathways. In the present work, we have identified novel partners that affect the E3-
ubiquitin ligase activity of the malin-laforin complex. First, we have studied which E2-
conjugase interacts with the complex. Since there are more than 38 genes encoding for E2 
enzymes in humans, and our group previously found evidence showing that the malin-laforin 
complex incorporates K63-linked ubiquitin chains (Moreno et al., 2010, Romá-Mateo et al., 
2011, Rubio-Villena et al., 2013), we centered our study in UBE2N, the only E2 with a known 
specificity for the incorporation of these type of chains (Eddins et al., 2006, Petroski et al., 
2007). Two complementary approaches were performed to assess the relevance of UBE2N 
on the malin-laforin complex mediated ubiquitination. First, it is known that mutation of the 
catalytic cysteine of an E2 enzyme to alanine provides a stable form which can no longer 
bind ubiquitin, but its overexpression has a dominant negative effect, impeding endogenous 
functional E2s to bind their putative E3s and transfer the ubiquitin. This approach has been 
successfully employed to study the interaction of UBE2N with other E3s (Slotman et al., 
2012), and for other E2 enzymes such as UBE2D2 (Gonen et al., 1999). Our results show 
that overexpression of the catalytically inactive version of UBE2N (UBE2N-C87A) drastically 
impairs the ubiquitination of different substrates by the malin-laforin complex. However, 
taking into account that the overexpression of this dominant negative mutant could affect the 
whole cellular ubiquitination machinery, we performed a complementary approach based on 
the specific silencing of the expression of the endogenous UBE2N. Again, when HEK293 
cells were silenced with specific siRNA against UBE2N, the activity of the malin-laforin 
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complex was diminished. Therefore, both approaches confirmed the participation of UBE2N 
in the malin-laforin complex mediated ubiquitination of different substrates. 
Despite the weak and transient nature of E2-E3 interactions, this binding is required 
for the transfer of ubiquitin to the substrate. The low affinity characteristics of this interaction 
may be due to the fact that E2s use the same surface to interact with E1s and E3s, and 
hence while binding to an E3 enzyme, they cannot be recharged with ubiquitin by an E1. 
Thus, binding of E2 to E3 is necessarily weak in order to allow E2 to be involved in repeated 
cycles of interaction with E1 and E3 (Ye and Rape, 2009). In this sense, traditional 
interaction analysis methodologies, such as the yeast two-hybrid system, may not be 
sensitive enough to detect the E2-E3 interaction, and perhaps for this reason we did not 
detect any two-hybrid interaction between UBE2N and laforin or malin. We obtained better 
results when using GFP-trap, a pull-down assay based on the use of anti-GFP antibodies 
which has been previously employed to detect this kind of weak interactions (Hoxhaj et al., 
2012). Using this technique, we observed that UBE2N interacted physically with the malin-
laforin complex, and our results also suggested a stronger interaction between UBE2N and 
malin. The interaction also occurred when the UBE2N-C87A form was used in the assay, 
although with reduced intensity. This latter result may suggest that binding between UBE2N 
and malin is increased if ubiquitin is attached to the E2, as already reported for other E2-E3 
complexes (Eddins et al., 2006). 
K63-linked ubiquitination of substrates has been related to autophagic degradation 
(Deshaies and Joazeiro, 2009, Tan et al., 2008). During this process, cargos are bound by 
specific adaptors which recognize both the ubiquitin chains and components in the 
autophagosome membrane, recruiting the substrates for their degradation (Lippai and Low, 
2014). Previous publications have shown a relationship between LD and autophagy (Aguado 
et al., 2010, Criado et al., 2012). Here, we show that one of the specific adaptors that 
mediates selective autophagy, p62 (SQSTM1), interacts with the malin-laforin complex. This 
interaction was not dependent on the ubiquitination state of the complex, since in the 
presence of UBE2N-C87A, which is unable to bind ubiquitin, the interaction of p62 with the 
complex was maintained. Remarkably, binding of p62 to the malin-laforin complex enhanced 
its E3-ubiquitin ligase activity. As the malin-laforin complex generates K63-linked 
polyubiquitin chains (Moreno et al., 2010, Romá-Mateo et al., 2011, Rubio-Villena et al., 
2013) and p62 seems to have a preference for this type of modifications (Seibenhener et al., 
2004), the interaction between the malin-laforin complex and p62 is in agreement with the 
clearance of malin-dependent substrates by autophagy. In addition, the fact that p62 is 
ubiquitinated by the malin-laforin complex with K63-ubiquitin linked chains might create a 
positive feedback loop where the modified p62 could recruit more p62, facilitating in this way 
its oligomerization, which would induce autophagy, as reported in other cases (Johansen and 
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Lamark, 2011, Shaid et al., 2013). We also present evidence indicating that malin-laforin 
complex and p62 form multimeric structures that are recognized by LC3 which would target 
them to the autophagosome (Fig. 8). 
In summary, we describe here two proteins that interact with the malin-laforin complex 
and modulate its ubiquitination activity. These new partners again highlight a link between 
proteins involved in LD and autophagy. Presumably, as we propose in Fig. 9, UBE2N 
interacts with the malin-laforin complex in order to promote the incorporation of K63-linked 
ubiquitin chains in the corresponding substrates. These chains would be recognized by p62, 
which would direct them to degradation via autophagy. This hypothesis would be in 
agreement with the previous observation that there is autophagy dysfunction in laforin- and 
malin-deficient mice (Aguado et al., 2010, Criado et al., 2012) and further corroborates the 
relevance of a functional malin-laforin complex in the maintenance of cellular protein 
homeostasis. 
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8.- FIGURE LEGENDS 
Fig. 1. E3 ubiquitin ligase activity of the malin-laforin complex depends on the activity 
of the E2-conjugase UBE2N. HEK293 cells were transfected with the indicated plasmids 
and ubiquitination analysis of different substrates carried out as described in Materials and 
Methods. A) Ubiquitination assays of laforin; B) Ubiquitination assays of R5/PTG. When 
indicated catalytically inactive forms of UBE2N (C87A) or UBE2D2 (C85A) were expressed. 
Proteins present in the bound fraction (Bound: proteins retained in the metal affinity resin) or 
in the crude extract (CE, 50 μg) were analyzed by Western blotting using the indicated 
antibodies (the fuzzy bands in the CE are probably due to the presence of 6 M guanidinium 
hydrochloride in the extracts). Molecular size markers are indicated. The position of 
ubiquitinated forms of the corresponding substrates is also indicated. A representative blot of 
three independent experiments is shown. 
 
Fig. 2. UBE2N silencing by siRNA diminishes the E3 activity of the malin-laforin 
complex. HEK293 cells were transfected with siRNA against UBE2N (+) or with negative 
control siRNA (-). Twenty-four hours after transfection, cells were transfected again with the 
corresponding plasmids and ubiquitination assays performed as indicated in Materials and 
Methods. A) Effect of UBE2N silencing on laforin ubiquitination; B) Effect of UBE2N silencing 
on R5/PTG ubiquitination (the two panels correspond to different areas of the same gel). 
Proteins present in the bound fraction (Bound: proteins retained in the metal affinity resin) or 
in the crude extract (CE, 50 μg) were analyzed by Western blotting using the indicated 
antibodies (the fuzzy bands in the CE are probably due to the presence of 6 M guanidinium 
hydrochloride in the extracts). Molecular size markers are indicated. The position of 
ubiquitinated forms of the corresponding substrates is also indicated. A representative blot of 
three independent experiments is shown. 
 
Fig. 3. The malin-laforin complex interacts physically with UBE2N. HEK293 cells were 
co-transfected with plasmids expressing HA-laforin, HA-malin and CFP (empty, UBE2N WT 
or UBE2N C87A). Cells were lysed and 1.5 mg of proteins were incubated with GFP-trap 
beads (Chromotek), which bind CFP forms with high affinity. After washing, beads were 
boiled in loading buffer and the purified proteins analyzed by SDS-PAGE and Western blot 
using anti-GFP and anti-HA antibodies. GFP-trap beads: proteins retained in the resin; C.E: 
crude extracts (50 μg of protein). A representative blot of three independent experiments is 
shown. 
 
Fig. 4. Overexpression of p62 (SQSTM1) enhances the ubiquitination activity of the 
malin-laforin complex. HEK293 cells were transfected with the indicated plasmids and 
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ubiquitination analysis of different substrates carried out as described in Materials and 
Methods. Proteins present in the bound fraction (Bound: proteins retained in the metal affinity 
resin) or in the crude extract (CE, 50 μg) were analyzed by Western blotting using the 
indicated antibodies (the fuzzy bands in the CE are probably due to the presence of 6 M 
guanidinium hydrochloride in the extracts). Molecular size markers are indicated. The 
position of ubiquitinated forms of the corresponding substrates is also indicated. A 
representative blot of three independent experiments is shown. 
 
Fig. 5. The E2 conjugase UBE2N participates in the malin-laforin dependent 
ubiquitination of p62, which is modified with K63-linked ubiquitin chains. A) 
Involvement of UBE2N in the ubiquitination of p62; B) Topology of the ubiquitination reaction. 
HEK293 cells were transfected with the indicated plasmids and ubiquitination analysis of 
different substrates carried out as described in Materials and Methods. Proteins present in 
the bound fraction (Bound: proteins retained in the metal affinity resin) or in the crude extract 
(CE, 50 μg) were analyzed by Western blotting using the indicated antibodies (the fuzzy 
bands in the CE are probably due to the presence of 6 M guanidinium hydrochloride in the 
extracts). Molecular size markers are indicated. The position of ubiquitinated forms of p62 is 
also indicated. A representative blot of three independent experiments is shown. 
 
Fig. 6. p62 interacts physically with the malin-laforin complex. HEK293 cells were co-
transfected with plasmids expressing CFP-laforin (or CFP alone), HA-malin, myc-p62 and 
myc-UBE2N (WT or C87A). Cells were lysed and 1.5 mg of proteins were incubated with 
GFP-trap beads (Chromotek), which bind CFP forms with high affinity. After washing, beads 
were boiled in loading buffer and the purified proteins analyzed by SDS-PAGE and Western 
blot using anti-GFP, anti-myc, anti-p62 and anti-HA antibodies. GFP-trap beads: proteins 
retained in the resin; C.E: crude extracts (50 μg of protein). A representative blot of three 
independent experiments is shown. 
 
Fig. 7. Immunofluorescence analyses confirm the interaction of the malin-laforin 
complex with p62. U2OS cells were transfected with the indicated plasmids. Then the 
subcellular localization of the corresponding proteins was analyzed either by direct 
fluorescence (in the case of CFP-fused proteins) or by immunofluorescence using anti-HA 
and anti-myc antibodies, as described in Materials and Methods. Fluorescence associated to 
the corresponding proteins was analyzed by confocal microscopy. A merge analysis of two or 
more fluorescent dyes is also presented. Bar: 30 m. 
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Fig. 8. Punctuated structures containing the malin-laforin complex and p62 co-localize 
with LC3, an autophagosomal marker. U2OS cells were transfected with the indicated 
plasmids. Then the subcellular localization of the corresponding proteins was analyzed either 
by direct fluorescence (in the case of GFP-fused proteins) or by immunofluorescence using 
anti-HA and anti-myc antibodies, as described in Materials and Methods. When indicated, 
cells also contained FLAG-laforin. Fluorescence associated to the corresponding proteins 
was analyzed by confocal microscopy. A merge analysis of two or more fluorescent dyes is 
also presented. Bar: 30 m. 
 
Fig. 9. Modulators of the ubiquitinating activity of the malin-laforin complex. The 
schematic representation shows the proposed physiological effects of UBE2N and p62 on 
the activity of the malin-laforin E3-ubiquitin ligase complex. UBE2N and p62 interact with the 
malin-laforin complex. UBE2N promotes the incorporation of the K63-linked ubiquitin chains 
into the corresponding substrate, being these chains recognized by p62. This modification 
will target the substrates for autophagy degradation, using p62 as a selective autophagy 
adaptor, which would interact with LC3, an autophagosomal marker. Ub, ubiquitin; UBA, 
ubiquitin associated binding domain; LIR, LC3-interacting region. See text for details. 
 
 
